[go: up one dir, main page]

WO2000069454A8 - Suppression of endogenous igfbp-2 to inhibit cancer - Google Patents

Suppression of endogenous igfbp-2 to inhibit cancer

Info

Publication number
WO2000069454A8
WO2000069454A8 PCT/US2000/013574 US0013574W WO0069454A8 WO 2000069454 A8 WO2000069454 A8 WO 2000069454A8 US 0013574 W US0013574 W US 0013574W WO 0069454 A8 WO0069454 A8 WO 0069454A8
Authority
WO
WIPO (PCT)
Prior art keywords
igfbp
modulators
cancer
cancers
suppression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/013574
Other languages
French (fr)
Other versions
WO2000069454A1 (en
WO2000069454A9 (en
Inventor
Shila Chakrabarty
Pomila Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO2000069454A1 publication Critical patent/WO2000069454A1/en
Publication of WO2000069454A8 publication Critical patent/WO2000069454A8/en
Anticipated expiration legal-status Critical
Publication of WO2000069454A9 publication Critical patent/WO2000069454A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)

Abstract

The present invention concerns the role of IGFBP-2 in cancer. Cancers that are dependent on IGFBP-2 would benefit from therapies targeting IGFBP-2. The invention discloses methods for inhibiting IGFBP-2 dependent cancers by modulating IGFBP-2 activity. Modulation can be achieved by decreasing the amounts of IGFBP-2 protein or IGFBP-2 activity, as well as other polypeptides that interact with or modify IGFBP-2. Preferred modulators of IGFBP-2 include antibodies specific for IGFBP-2 and antisense or ribozymes specific for IGFBP-2 nucleic acid. These modulators are useful for treating cancers derived from any tissue, with cancer of the prostate being preferred. Methods of treating a subject with cancer are disclosed as well as compositions of IGFBP-2 modulators and kits containing such modulators.
PCT/US2000/013574 1999-05-17 2000-05-17 Suppression of endogenous igfbp-2 to inhibit cancer Ceased WO2000069454A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13458199P 1999-05-17 1999-05-17
US60/134,581 1999-05-17

Publications (3)

Publication Number Publication Date
WO2000069454A1 WO2000069454A1 (en) 2000-11-23
WO2000069454A8 true WO2000069454A8 (en) 2001-04-12
WO2000069454A9 WO2000069454A9 (en) 2002-04-18

Family

ID=22464011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/013574 Ceased WO2000069454A1 (en) 1999-05-17 2000-05-17 Suppression of endogenous igfbp-2 to inhibit cancer

Country Status (1)

Country Link
WO (1) WO2000069454A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001290920B2 (en) 2000-09-14 2006-11-23 The University Of British Columbia Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy
FR2821624B1 (en) 2001-03-01 2004-01-02 Sod Conseils Rech Applic NEW POLYNUCLEOTIDE FOR USE IN MODULATING THE PROLIFERATION OF CANCER CELLS
WO2002090580A1 (en) * 2001-05-03 2002-11-14 National Cancer Centre Of Singapore Pte Ltd Identifying liver cancer by detecting aberrant expression of insulin like growth factor binding protein
CA2469685C (en) 2002-01-17 2013-03-12 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
KR101086533B1 (en) 2002-05-24 2011-11-23 쉐링 코포레이션 Neutralizing human anti-IGFR antibody, method for preparing same, and composition comprising same
KR101117673B1 (en) 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 RNAi Probes Targeting Cancer-Related Proteins
WO2005030260A1 (en) 2003-10-01 2005-04-07 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
JP2007510434A (en) 2003-11-12 2007-04-26 シェーリング　コーポレイション A plasmid system for multigene expression.
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
EP2283831A3 (en) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomakers for pre-selection of patients for anti-IGF1R therapy
CA2659585A1 (en) * 2006-08-16 2008-02-21 National Research Council Of Canada Inhibition of angiogenesis, tumorigenesis and cathepsin activity using insulin-like growth factor binding protein
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
CA3146962A1 (en) 2011-02-11 2012-08-16 The Rockefeller University Treatment of angiogenesis disorders
CN102590511B (en) * 2012-02-14 2014-07-23 北京市肿瘤防治研究所 Tumor diagnosis reagent or kit based on detection of IGFBP-2 (insulin-like growth factor binding protein 2) autoantibody or combined detection of IGFBP-2 antoantibody and IGFBP-2, as well as application thereof

Also Published As

Publication number Publication date
WO2000069454A1 (en) 2000-11-23
WO2000069454A9 (en) 2002-04-18

Similar Documents

Publication Publication Date Title
WO2000069454A8 (en) Suppression of endogenous igfbp-2 to inhibit cancer
WO1999022773A3 (en) Sequences for targeting metastatic cells
MXPA00007388A (en) Methods for treating skin pigmentation.
WO1996035784A3 (en) Chromatin-regulator genes
WO2002022685A3 (en) Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
WO2001091805A3 (en) Compounds for targeting endothelial cells
WO2001023405A3 (en) Therapeutic treatment of androgen receptor driven conditions
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO1999014346A3 (en) SENSE mRNA THERAPY
TR199902053T2 (en) Compounds for immunotherapy of prostate cancer and methods for their use.
WO2004039955A3 (en) Modulators of angiogenesis and tumorigenesis
WO1998000532A3 (en) Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
WO2001014584A3 (en) Methods of identifying anti-viral agents
WO2002004522A3 (en) Bifunctional molecules and vectors complexed therewith for targeted gene delivery
ATE275956T1 (en) ALTERATION OF DNA METHYLTRANSFERASE THROUGH COMBINATION THERAPY
WO2002011762A3 (en) Methods and compositions for modulating tumor growth
PL346246A1 (en) Modulating multiple lineage kinase proteins
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
WO2000034447A8 (en) Human ubiquitin ligase e3 for the modulation of nf-kappa b
EP0943620A3 (en) Betulinic acid derivatives for inhibiting cancer growth
WO2002054066A3 (en) Non-apoptotic forms of cell death and methods of modulation
ZA200007321B (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase Src.
WO2000017346A3 (en) Hairpin hybridizer molecules for modulation of gene expression
DE69739167D1 (en) COMPOSITIONS FOR MODULATING THE LENGTH OF TELOMERS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/8-8/8, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP